2023-05-24 09:54:18 ET
- Phio Pharmaceuticals ( NASDAQ: PHIO ) stock rose ~12% on Wednesday after the company said its clinical development partner AgonOx in collaboration with Providence Cancer Institute completed a site initiation visit and can start patient accrual.
- The trial will evaluate enhanced therapeutic benefit from administering Phio's PH-762 treated 'double positive' (DP) CD8 tumor infiltrating lymphocytes (TILs) in patients with melanoma and other advanced solid tumors. The study will test PH-762 in combination with AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148).
- Phio noted that it had received FDA clearance to start a trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The study is expected to begin in H2 2023.
For further details see:
Phio stock rises ~12% as cancer drug trial set for patient enrollment